Soluble Receptor for Advanced Glycation End Products Improves Stromal Cell-Derived Factor-1 Activity in Model

Melissa Przyborowski Olekson1, Renea A Faulknor1, Henry C Hsia2

  • 1Department of Biomedical Engineering, Rutgers University , Piscataway, New Jersey.

Advances in Wound Care
|January 13, 2017
PubMed

Insights

Blocking the receptor for advanced glycation end products (RAGE) with soluble RAGE (sRAGE) can restore cellular responses in diabetic wounds. This approach enhances the effectiveness of stromal cell-derived factor-1 (SDF-1) for wound healing.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Wound Healing Research

Background:

  • Hyperglycemia in diabetes leads to advanced glycation end products (AGEs) accumulation.
  • AGEs trigger reactive oxygen species (ROS) via the receptor for AGEs (RAGE).
  • Exogenous growth factors show limited success in diabetic wound healing.

Purpose of the Study:

  • Investigate if AGEs interfere with cellular responses to extracellular signals in diabetes.
  • Assess the role of stromal cell-derived factor-1 (SDF-1) in this context.
  • Determine if blocking RAGE can improve diabetic wound healing.

Main Methods:

  • Incubation of human leukemia-60 (HL-60) cells and mouse peripheral blood mononuclear cells (PBMCs) in high glucose medium.
  • Use of soluble RAGE (sRAGE) to block RAGE activation.
  • Assays for cellular migration, ROS generation, and in vivo wound healing in a diabetic murine model.

Main Results:

  • Hyperglycemia increased AGEs, decreased SDF-1-directed migration, and elevated baseline ROS.
  • SDF-1 failed to induce normal ROS spikes in hyperglycemic conditions.
  • sRAGE reduced baseline ROS, restored SDF-1-mediated migration and ROS spikes, and promoted wound healing in vivo.

Conclusions:

  • Blocking RAGE with sRAGE restores SDF-1-mediated cellular responses in hyperglycemic environments.
  • sRAGE potentiates the effectiveness of exogenously applied SDF-1 in diabetic wound healing.
  • This strategy offers a potential therapeutic avenue for diabetic wound complications.